Clinical Trials Browser

Colonic Neoplasms, Colorectal Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

39 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

123 enrolled 21 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06425133 2024-12-24

CARE

Phase 2 Recruiting

174 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04534218 2024-12-20

REPROGRAM-01

Phase 2 Completed

49 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Phase 2 Active not recruiting

12 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05900648 2024-04-29

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02664077 2022-04-14

ARGO

Phase 3 Terminated

34 enrolled

Gastrointestinal

Colonic Neoplasms

NCT02425683 2020-02-10

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Phase 2 Terminated

24 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02402036 2019-01-29

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Phase 2 Terminated

10 enrolled 8 charts

Gastrointestinal

Colonic Neoplasms

NCT02119676 2018-02-13

Study of Ruxolitinib in Colorectal Cancer Patients

Phase 2 Terminated

396 enrolled 15 charts

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Colorectal Neoplasms

Clinical Trials

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

CARE

REPROGRAM-01

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

ARGO

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

Study of Ruxolitinib in Colorectal Cancer Patients